James T. Dalton

Structural basis for antagonism and resistance of bicalutamide in prostate cancer

Casey E. Bohl, Wenqing Gao, Duane D. Miller et al. · Proceedings of the National Academy of Sciences · 2005 · 418 citations · Full text

Medicine, Oncology, Pharmacology +17

The selective androgen receptor modulator GTx‐024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double‐blind, placebo‐controlled phase II trial

James T. Dalton, K. Gary Barnette, Casey E. Bohl et al. · Journal of Cachexia Sarcopenia and Muscle · 2011 · 390 citations · Full text

Medicine, Endocrinology, Pharmacology +17

Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia

John C. Byrd, Thomas S. Lin, James T. Dalton et al. · Blood · 2006 · 388 citations · Full text

Medicine, Oncology, Pharmacology +7

Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial

Adrian S. Dobs, Ralph V. Boccia, C. Croot et al. · The Lancet Oncology · 2013 · 383 citations

Medicine, Oncology, Pharmacotherapy +11

Discovery of Nonsteroidal Androgens

James T. Dalton, Arnab Mukherjee, Zixin Zhu et al. · Biochemical and Biophysical Research Communications · 1998 · 224 citations · Full text

Life Sciences, Biochemistry, Endocrinology +12